



SDI Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_48076
Title of the Manuscript:	QSAR and docking study of isatin analogues As cytotoxic agent
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	<ol style="list-style-type: none"> 1) In page no.4, n oxim, n pyridine, n isothiocyanate, n thiocyanate , nC=S, nArNO₂, n oxazole, nThiazol, nCOOH, nCOOCH. Specify as what it is in manuscript. 2) In conclusion part, analysis show positive effect of the n oxim, n pyridine, n isothiocyanate, n thiocyanate on the anti-cancer activity and it also indicate the nC=S, nArNO₂, n oxazole, nThiazol, nCOOH, nCOOCH have negative effects on activity.Doe it has any relation with the structure? 	All of descriptor was explained, and highlighted in the manuscript.
Minor REVISION comments	A lot of spelling mistakes, please spell check.	It was corrected
Optional/General comments		

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	